Ambit Biosciences

In June 2010, Ambit completed a Series D-2 round of equity financing, raising $30 million in new capital.^[5] The investor syndicate was led by Apposite Capital LLP and included existing investors such as Perseus-Soros Biopharmaceutical Fund, OrbiMed Advisors, Forward Ventures, Roche Venture Fund, MedImmune Ventures, GIMV, GrowthWorks, Genechem, Radius Ventures, NovaQuest and Horizon Technology Finance.^[6]

As of March 2014^[update], Ambit sought to develop new therapeutics through internal, proprietary research, which is evidenced by their pipeline of three products consisting entirely of internally developed therapeutics.^[1]: 3 Further, Ambit aimed to be a full life cycle pharmaceutical company by conducting discovery, development and further commercialization of therapeutics.^[1]: 3

Among the firms who invested heavily in Ambit prior to its initial public offering was Foresite Capital in January 2013.^[3]

In November 2014, Ambit was acquired by Daiichi Sankyo.^[7] The prime asset that drove this deal was Ambit's quizartinib (AC220).^{[clarification needed][8]}